Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 10 | 2023 | 2518 | 1.130 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 15694 | 0.930 |
Why?
|
| Azadirachta | 2 | 2011 | 2 | 0.810 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2011 | 363 | 0.690 |
Why?
|
| Plant Extracts | 2 | 2011 | 215 | 0.680 |
Why?
|
| NF-kappa B | 6 | 2011 | 1549 | 0.650 |
Why?
|
| Neuroblastoma | 4 | 2011 | 686 | 0.640 |
Why?
|
| Estrogen Receptor alpha | 4 | 2021 | 701 | 0.620 |
Why?
|
| Trastuzumab | 7 | 2023 | 696 | 0.610 |
Why?
|
| Gamma Rays | 3 | 2011 | 242 | 0.540 |
Why?
|
| Gene Fusion | 1 | 2016 | 209 | 0.510 |
Why?
|
| Curcumin | 2 | 2011 | 117 | 0.470 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 187 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 8873 | 0.450 |
Why?
|
| Signal Transduction | 14 | 2021 | 11965 | 0.430 |
Why?
|
| Rosaceae | 1 | 2011 | 2 | 0.420 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 184 | 0.390 |
Why?
|
| Carrier Proteins | 2 | 2020 | 2022 | 0.380 |
Why?
|
| Digestive System | 1 | 2010 | 114 | 0.370 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 266 | 0.370 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 783 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5178 | 0.360 |
Why?
|
| Apoptosis | 5 | 2019 | 7591 | 0.350 |
Why?
|
| Quinazolines | 3 | 2023 | 923 | 0.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 852 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1538 | 0.260 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 2086 | 0.260 |
Why?
|
| Genomics | 1 | 2016 | 2738 | 0.260 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 755 | 0.260 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 14551 | 0.240 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 5159 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14289 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 5 | 2023 | 4975 | 0.220 |
Why?
|
| Mice, Nude | 4 | 2020 | 4307 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 15862 | 0.210 |
Why?
|
| Protein Kinases | 2 | 2016 | 874 | 0.210 |
Why?
|
| Biomarkers, Tumor | 6 | 2023 | 10331 | 0.210 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 1519 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 521 | 0.200 |
Why?
|
| Plant Leaves | 2 | 2011 | 61 | 0.200 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 726 | 0.200 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 98 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 129 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.180 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 34 | 0.180 |
Why?
|
| Cinnamates | 1 | 2018 | 27 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2020 | 314 | 0.160 |
Why?
|
| Cell Survival | 4 | 2021 | 3045 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 348 | 0.160 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 4 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 342 | 0.150 |
Why?
|
| Brain | 1 | 2010 | 4113 | 0.150 |
Why?
|
| Female | 19 | 2023 | 141928 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2016 | 731 | 0.140 |
Why?
|
| Mice | 9 | 2021 | 34495 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 840 | 0.130 |
Why?
|
| Humans | 25 | 2023 | 261506 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 984 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3821 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 5061 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2014 | 250 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1244 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 4849 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 2330 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1009 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 1756 | 0.110 |
Why?
|
| Animals | 9 | 2021 | 59536 | 0.110 |
Why?
|
| Cell Separation | 1 | 2014 | 612 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 666 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 27 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2019 | 1154 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 2216 | 0.100 |
Why?
|
| Aminoquinolines | 1 | 2011 | 46 | 0.100 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 54 | 0.100 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 136 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4757 | 0.100 |
Why?
|
| Gene Expression | 1 | 2020 | 3570 | 0.100 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 170 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 650 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 651 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 1678 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 177 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2054 | 0.090 |
Why?
|
| Fruit | 1 | 2011 | 294 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 5395 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 4938 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7226 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2483 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 1399 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1439 | 0.080 |
Why?
|
| Telomerase | 1 | 2011 | 525 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 4821 | 0.080 |
Why?
|
| Time Factors | 2 | 2011 | 12926 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 32848 | 0.070 |
Why?
|
| Cell Movement | 1 | 2014 | 2466 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 6295 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 1070 | 0.070 |
Why?
|
| Transfection | 1 | 2011 | 2944 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3981 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 550 | 0.070 |
Why?
|
| Prognosis | 4 | 2021 | 21713 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 876 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2011 | 3154 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3203 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 3639 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1129 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6150 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2295 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 2693 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2021 | 4804 | 0.050 |
Why?
|
| Models, Biological | 1 | 2010 | 3254 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13658 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 2809 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 6942 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 371 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 265 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 447 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2016 | 2450 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1077 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 478 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 862 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 76 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 848 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 733 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 5437 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 748 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 751 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2009 | 1014 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 375 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1344 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 837 | 0.030 |
Why?
|
| Remission Induction | 1 | 2020 | 3569 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3890 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 2084 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 250 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7789 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 2508 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 18 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6009 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 671 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 119 | 0.020 |
Why?
|
| Middle Aged | 3 | 2020 | 86204 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9180 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1869 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7222 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 629 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 534 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1910 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 70117 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 854 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 3101 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 77950 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3230 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 29902 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 15179 | 0.010 |
Why?
|